A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)

A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)

Saved in:

Bibliographic Details
Main Authors:	Chao Zhang, Jiaqi Wen, Yinghui Li
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140211/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
by: Bangbei Wan, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
by: Yun Li, et al.
Published: (2025-01-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV
by: Anton Pozniak, et al.
Published: (2025-04-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system
by: Lingti Kong, et al.
Published: (2025-05-01)

A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database
by: Yi Yin, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Qinhui Tang, et al.
Published: (2025-01-01)

Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
by: Qinhui Tang, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
by: Yongfu Song, et al.
Published: (2025-03-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
by: Chengyu Zhu, et al.
Published: (2025-03-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Neurological adverse events associated with baclofen: A disproportionality analysis based on FDA Adverse Event Reporting System
by: Ni Zhang, et al.
Published: (2025-04-01)

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system
by: Cheng Jiang, et al.
Published: (2025-07-01)

Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis
by: Lijun Li, et al.
Published: (2025-01-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis.
by: Lijun Li, et al.
Published: (2025-01-01)

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
by: Jing Shi, et al.
Published: (2025-03-01)

Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024.
by: Xiaoling Zhong, et al.
Published: (2025-01-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database
by: Ping Huang, et al.
Published: (2024-10-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024
by: Fengjie Tang, et al.
Published: (2025-05-01)